Profil
Chengwen Li is the founder of GeneVentiv Therapeutics, Inc. He currently holds a position as Director at Nabgen, Inc.
Postes actifs de Chengwen Li
| Sociétés | Poste | Début |
|---|---|---|
GeneVentiv Therapeutics, Inc.
 GeneVentiv Therapeutics, Inc. BiotechnologyHealth Technology GeneVentiv Therapeutics, Inc. is a company that is developing the first gene therapy for patients with hemophilia A or B, with or without inhibitors. The company is based in Raleigh, NC. The company's product, Genv-Hem, produces clotting factor Va, which allows for normal clotting in response to injury. Currently, there are no curative gene therapies available for patients with inhibitors. GeneVentiv Therapeutics was founded by Chengwen Li and the CEO is Damon R Race. | Fondateur | - |
| Nabgen, Inc. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
GeneVentiv Therapeutics, Inc.
GeneVentiv Therapeutics, Inc. BiotechnologyHealth Technology GeneVentiv Therapeutics, Inc. is a company that is developing the first gene therapy for patients with hemophilia A or B, with or without inhibitors. The company is based in Raleigh, NC. The company's product, Genv-Hem, produces clotting factor Va, which allows for normal clotting in response to injury. Currently, there are no curative gene therapies available for patients with inhibitors. GeneVentiv Therapeutics was founded by Chengwen Li and the CEO is Damon R Race. | Health Technology |
| Nabgen, Inc. |
